Showing results (541-550 of 569) with videos related to

Sort By:
Pageof 57
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Infectious Diseases and Therapy|July 11, 2023
Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort StudiesIain A Gillespie, Eleanor Barnes, Ian C K Wong, et al.
Open Research Europe|August 30, 2023
ECORISK2050: An Innovative Training Network for predicting the effects of global change on the emission, fate, effects, and risks of chemicals in aquatic ecosystemsSamuel A Welch, Taylor Lane, Alizée O S Desrousseaux, et al.
Molecular Cancer Therapeutics|April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analoguesSwee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Journal of Medicinal Chemistry|November 22, 2013
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)Sébastien Naud, Isaac M Westwood, Amir Faisal, et al.
Integrated Environmental Assessment and Management|September 8, 2010
Environmental risk assessment of ivermectin: A case studyMarkus Liebig, Alvaro Alonso Fernandez, Elke Blübaum-Gronau, et al.
BJUI Compass|January 29, 2025
The significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: Results from the IDENTIFY studySinan Khadhouri, Kevin Gallagher, Kenneth R MacKenzie, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Integrated Environmental Assessment and Management|July 6, 2019
Towards Sustainable Environmental Quality: Priority Research Questions for the Australasian Region of OceaniaSally Gaw, Andrew Harford, Vincent Pettigrove, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 57